Proposed to stimulate lipolysis and inhibit lipogenesis without the IGF-1 mediated effects of full-length growth hormone.
What was measuredHuman trials did not show weight loss beyond placebo. The encouraging animal data did not replicate in people.
Also known as hGH fragment 176-191 · developed by Metabolic Pharmaceuticals
Taken into human trials and did not outperform placebo on its primary endpoint, or development was discontinued. This is stronger evidence than "untested" — it is evidence of absence, not absence of evidence.
A fragment of the C-terminus of human growth hormone, developed specifically as a weight-loss drug on the theory that the fat-metabolising properties of growth hormone could be separated from its growth effects.
Proposed to stimulate lipolysis and inhibit lipogenesis without the IGF-1 mediated effects of full-length growth hormone.
A 12-week randomised placebo-controlled trial in obese participants found no significant difference in weight loss versus placebo. Development for obesity was discontinued.
Rodent studies had shown reductions in body fat. This is a clear worked example of animal results failing to carry over to humans.
This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.
Not approved as a medicine anywhere. Marketed in some places as a supplement ingredient, which regulators including the FDA have challenged.
The sites below are where AOD-9604 is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.
Drag to turn · tap an organ
Proposed to stimulate lipolysis and inhibit lipogenesis without the IGF-1 mediated effects of full-length growth hormone.
What was measuredHuman trials did not show weight loss beyond placebo. The encouraging animal data did not replicate in people.
A long-acting analogue of GLP-1, a hormone the gut releases after eating. Structural changes — an Aib substitution that …
A single molecule that activates two incretin receptors — GIP and GLP-1 — built on a GIP backbone with substitutions tha…
An investigational agonist at three receptors — GIP, GLP-1 and glucagon. The glucagon component is what distinguishes it…
This site publishes summaries of published research. It is not medical advice, and Genexis Health does not sell or supply any compound described here. Please confirm each statement below to continue.
We ask everyone to confirm they understand this site is information rather than medical advice before reading it. Because you have not confirmed those statements, you cannot continue.
If you are looking for health advice or treatment, please speak to a licensed healthcare professional. Nothing on this site is a substitute for that.